Spinal cord stimulation for the treatment of neuropathic pain: expert opinion and 5-year outlook
MN Malinowski, S Jain, N Jassal… - Expert Review of Medical …, 2020 - Taylor & Francis
MN Malinowski, S Jain, N Jassal, T Deer
Expert Review of Medical Devices, 2020•Taylor & FrancisIntroduction Spinal cord stimulation (SCS) is an effective treatment for chronic, intractable
neuropathic pain. There have been relatively few high-level studies that suggest its
unequivocal use. The decay of stimulation efficacy over time have opened opportunity for
the entrance of new pulse trains and waveforms. Areas covered In this state-of-the-art
review, we focused on many of the major studies published in the last 10 years that were
considered level one evidence. A retrospective narrative approach was taken to …
neuropathic pain. There have been relatively few high-level studies that suggest its
unequivocal use. The decay of stimulation efficacy over time have opened opportunity for
the entrance of new pulse trains and waveforms. Areas covered In this state-of-the-art
review, we focused on many of the major studies published in the last 10 years that were
considered level one evidence. A retrospective narrative approach was taken to …
Introduction
Spinal cord stimulation (SCS) is an effective treatment for chronic, intractable neuropathic pain. There have been relatively few high-level studies that suggest its unequivocal use. The decay of stimulation efficacy over time have opened opportunity for the entrance of new pulse trains and waveforms.
Areas covered
In this state-of-the-art review, we focused on many of the major studies published in the last 10 years that were considered level one evidence. A retrospective narrative approach was taken to conceptualize foundation studies as they pertain to current evidence. A special focus was taken on reported safety outcomes in comparison to foundation studies especially as they pertain to our 5-year outlook on the use of spinal cord stimulation.
Expert opinion
We find there are still significant limitations in the body of reviewed evidence and suggest that long-term data beyond 24 months are lacking in the literature. In addition, adverse event rates, device explantation rates and the sham effect looms as important concepts to address in the future in spite of the existing novel stimulation paradigms.
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果